Diabetes Self-Management Blog

The surprising and much-publicized early findings from the ACCORD study, which showed a slightly increased risk of death among certain people with Type 2 diabetes who used intensive drug therapy to lower blood glucose levels, have prompted researchers conducting a similar ongoing study to release early results. The ADVANCE study, which is the largest study ever of aggressive blood glucose control in people with Type 2 diabetes, has found no increase in risk of death associated with intensive treatment.

The ADVANCE trial’s 11,140 participants were followed over an average period of five years. The blood-glucose-lowering arm of the study ended in January, and confirmation of the data was more than 99% complete in mid-February according to the study’s director.

In several important ways, the studies are alike. For example, the populations in both studies were similar, with about one-third of the participants in each having a history of cardiovascular disease before the studies began. Both studies randomly divided participants into intensive-control and standard-control groups with regard to HbA1c levels (blood glucose levels over time). And in both studies, the intensive-control groups achieved the same average HbA1c level: 6.4% (although in the ACCORD trial the group was aiming for less than 6% and in the ADVANCE trial the group aimed for 6.5%). But, unlike the ACCORD researchers, the ADVANCE group—which says it is working with twice as much data as the ACCORD trial provided—has so far found “no indication of harm” associated with achieving this HbA1c level.

Until more analysis is done, the researchers will not be able to explain why the studies may have come up with different results. In addition, some differences between the two studies will need to be considered. For example, it is likely that different combinations of drugs were used to achieve intensive blood glucose control in the studies; once full analysis of the data from ADVANCE is complete, researchers will know more about these potential differences in treatment. There were also differences in the average age of participants (66 years old for ADVANCE; 62 years old for ACCORD), years of living with diabetes before the trials began (8 years for ADVANCE; 10 years for ACCORD), blood pressure levels at the beginning of the studies (higher in ADVANCE than in ACCORD), and HbA1c levels at the beginning of the studies (lower in ADVANCE than in ACCORD). The ADVANCE researchers will need to analyze all of these factors before they can draw conclusions about the risks and benefits of intensive blood glucose control in high-cardiovascular-risk groups of people with Type 2 diabetes. The ACCORD and ADVANCE investigators also have some joint analyses of data planned.

The ADVANCE trial, which took place at The George Institute for International Health at the University of Sydney in Australia, was funded in part by the pharmaceutical company Servier, which manufactures one of the drugs (the sulfonylurea gliclazide [brand name Diamicron], which is not marketed in the United States) that was used by all members of the intensive-control group in the trial.

A variety of pharmaceutical companies contributed drugs, equipment, or supplies to the ACCORD trial.

In a statement, the American Diabetes Association said that it plans to “critically examine the final data from these studies once they are publicly available later this year and will issue further recommendations at that time.” In the meantime, however, it continues to promote a general goal of an HbA1c level under 7% for people with diabetes, with higher or lower individualized goals possible based on people’s individual situations.

You can read more of DiabetesSelfManagement.com’s coverage of the ACCORD trial results in the blog entries “The ACCORD Trial Findings: What You Should Know,” “ACCORD Travesty,” and “What We’re Reading: Reactions to ACCORD.”


  1. Again it would be nice if one of our professional writers could interview Dr. Herschel Gerstein at McMaster University in beautiful Hamilton,(between Toronto and Buffalo)being on both study he could put this in the proper perspective once the analysis are done. Not to put words in the good DR. mouth I predict that he will say that there is nothing wrong with Keeping your blood sugar in the same range as a non diabetic.

    Posted by CalgaryDiabetic |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of Madavor Media, LLC., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.

Type 2 Diabetes
Discovering I Had Type 2 Diabetes (10/17/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)
Metformin Study Currently Recruiting (08/19/14)

Heart Health
Self-Manage Your Blood Pressure (09/02/14)
Pistachios Offer Protection for People With Diabetes (08/29/14)
Which Butter (or Spread) Is Better? (07/28/14)
High-Salt Diet Doubles Heart Risk in Type 2 Diabetes (07/25/14)

Diabetes Research
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)
Statins May Reduce Risk of Nerve Damage, Other Diabetes Complications (09/18/14)

Diabetes News
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)
New Weekly Type 2 Diabetes Drug Approved (09/26/14)



Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.

Blood Glucose Self-Monitoring — Part 3: Smart Monitoring

10 Keys to Long-Term Weight Loss

Take Your Best Shot: Stay Up to Date on Vaccines

Complete table of contents
Subscription questions